Physician profile
Ali Hammoud
NPI 1801899877
$2,679.73
in general payments reported to CMS, 2019-2025
19 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,678 · 2020: $125 · 2023: $149 · 2024: $278 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $661.86 | 2019-2025 | |
| Amgen INC. | $579.20 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $307.01 | 2019-2020 | |
| Abbott Laboratories | $264.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $203.72 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $92.49 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $89.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $89.44 | 2019-2024 | Eliquis, Camzyos |
| Lundbeck LLC | $78.76 | 2019 | |
| Medtronic, INC. | $73.67 | 2023 | Open Pivot |
| Novo Nordisk INC | $45.80 | 2025 | |
| Amarin Pharma, INC. | $38.47 | 2019 | |
| Pfizer INC. | $34.43 | 2019-2023 | |
| Cvrx, INC. | $28.33 | 2023 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $23.88 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $21.08 | 2019 | |
| Lilly USA, LLC | $16.23 | 2025 | Zepbound, Mounjaro |
| Medicomp INC | $15.93 | 2019 | |
| Medtronic Vascular, INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hammoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.